{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:14:46Z","timestamp":1787026486701,"version":"build-2736575974"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Monoclonal gammopathies result from neoplastic clones of the B-cell lineage and may cause kidney disease by various mechanisms. When the underlying clone does not meet criteria for a malignancy requiring treatment, the paraprotein is called a monoclonal gammopathy of renal significance (MGRS). One rarely reported kidney lesion associated with benign paraproteins is thrombotic microangiopathy (TMA), provisionally considered as a combination signifying MGRS. Such cases may lack systemic features of TMA, such as a microangiopathic hemolytic anemia, and the disease may be kidney limited. There is no direct deposition of the paraprotein in the kidney, and the presumed mechanism is disordered complement regulation. We report three cases of kidney limited TMA associated with benign paraproteins that had no other detectable cause for the TMA, representing cases of MGRS. Two of the cases are receiving clone directed therapy, and none are receiving eculizumab. We discuss in detail the pathophysiological basis for this possible association. Our approach to therapy involves first ruling out other causes of TMA as well as an underlying B-cell malignancy that would necessitate direct treatment. Otherwise, clone directed therapy should be considered. If refractory to such therapy or the disease is severe and multisystemic, C5 inhibition (eculizumab or ravulizumab) may be indicated as well.<\/jats:p>","DOI":"10.3389\/fimmu.2021.780107","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T04:36:30Z","timestamp":1636518990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Thrombotic Microangiopathy, an Unusual Form of Monoclonal Gammopathy of Renal Significance: Report of 3 Cases and Literature Review"],"prefix":"10.3389","volume":"12","author":[{"given":"Edward J.","family":"Filippone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000096761","article-title":"Mechanisms of Renal Damage in Plasma Cell Dyscrasias: An Overview","volume":"153","author":"Merlini","year":"2007","journal-title":"Contrib Nephrol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02260","article-title":"Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy","volume":"9","author":"Chauvet","year":"2018","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023144","article-title":"Molecular Mechanisms of Amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-872028","article-title":"Randall-Type Monoclonal Immunoglobulin Deposition Disease: Novel Insights From a Nationwide Cohort Study","volume":"133","author":"Joly","year":"2019","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.kint.2018.02.020","article-title":"A Clone-Directed Approach may Improve Diagnosis and Treatment of Proliferative Glomerulonephritis With Monoclonal Immunoglobulin Deposits","volume":"94","author":"Gumber","year":"2018","journal-title":"Kidney Int"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The Evaluation of Monoclonal Gammopathy of Renal Significance: A Consensus Report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1810907","article-title":"Monoclonal Gammopathy of Renal Significance","volume":"384","author":"Leung","year":"2021","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1410951","article-title":"Syndromes of Thrombotic Microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13571","article-title":"Consensus on the Standardization of Terminology in Thrombotic Thrombocytopenic Purpura and Related Thrombotic Microangiopathies","volume":"15","author":"Scully","year":"2017","journal-title":"J Thromb Haemost"},{"key":"B10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and Outcomes of Thrombotic Microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ekir.2020.10.009","article-title":"Complement in Secondary Thrombotic Microangiopathy","volume":"6","author":"Palma","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136094","article-title":"Complementopathies and Precision Medicine","volume":"130","author":"Gavriilaki","year":"2020","journal-title":"J\u00a0Clin Invest"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.10.006","article-title":"AJKD Atlas of Renal Pathology: Thrombotic Microangiopathy","volume":"68","author":"Lusco","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy: Conclusions From a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00620117","article-title":"Thrombotic Microangiopathy and the Kidney","volume":"13","author":"Brocklebank","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1681\/ASN.2014050429","article-title":"Complement Factor C4d Is a Common Denominator in Thrombotic Microangiopathy","volume":"26","author":"Chua","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1136\/jmg.2005.030783","article-title":"The Development of Atypical Haemolytic-Uraemic Syndrome Is Influenced by Susceptibility Factors in Factor H and Membrane Cofactor Protein: Evidence From Two Independent Cohorts","volume":"42","author":"Fremeaux-Bacchi","year":"2005","journal-title":"J Med Genet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddi066","article-title":"Predisposition to Atypical Hemolytic Uremic Syndrome Involves the Concurrence of Different Susceptibility Alleles in the Regulators of Complement Activation Gene Cluster in 1q32","volume":"14","author":"Esparza-Gordillo","year":"2005","journal-title":"Hum Mol Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.01.023","article-title":"Atypical and Secondary Hemolytic Uremic Syndromes Have a Distinct Presentation and No Common Genetic Risk Factors","volume":"95","author":"Le Clech","year":"2019","journal-title":"Kidney Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","article-title":"Clinical Features of Anti-Factor H Autoantibody\u2013Associated Hemolytic Uremic Syndrome","volume":"21","author":"Dragon-Durey","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1681\/ASN.2020081224","article-title":"IgM Autoantibodies to Complement Factor H in Atypical Hemolytic Uremic Syndrome","volume":"32","author":"Cugno","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2215\/CJN.05750611","article-title":"Factor I Autoantibodies in Patients With Atypical Hemolytic Uremic Syndrome: Disease-Associated or an Epiphenomenon","volume":"7","author":"Kavanagh","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","article-title":"Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype","volume":"5","author":"Noris","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.03.885","article-title":"Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality","volume":"6","author":"Ardissino","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1681\/ASN.2012090884","article-title":"Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype","volume":"24","author":"Bresin","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.4049\/jimmunol.1302288","article-title":"Generation of Multiple Fluid-Phase C3b:Plasma Protein Complexes During Complement Activation: Possible Implications in C3 Glomerulopathies","volume":"192","author":"Ramadass","year":"2014","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1086\/318201","article-title":"Clustering of Missense Mutations in the C-Terminal Region of Factor H in Atypical Hemolytic Uremic Syndrome","volume":"68","author":"P\u00e9rez-Caballero","year":"2001","journal-title":"Am J Hum Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.1681\/ASN.2015020184","article-title":"Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach","volume":"26","author":"De Vriese","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr422","article-title":"Thrombotic Microangiopathy Mimicking Membranoproliferative Glomerulonephritis","volume":"26","author":"Brackman","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2007.11.032","article-title":"Complement Factor H Deficiency and Posttransplantation Glomerulonephritis With Isolated C3 Deposits","volume":"51","author":"Boyer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr436","article-title":"Three Kidneys, Two Diseases, One Antibody","volume":"26","author":"Lorcy","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-012-2210-0","article-title":"Membrano-Proliferative Glomerulonephritis, Atypical Hemolytic Uremic Syndrome, and a New Complement Factor H Mutation: Report of a Case","volume":"27","author":"Gnappi","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5000155","article-title":"Phenotypic Expression of Factor H Mutations in Patients With Atypical Hemolytic Uremic Syndrome","volume":"69","author":"Vaziri-Sani","year":"2006","journal-title":"Kidney Int"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-Cell Disorder Improves Renal Outcome of Patients With Monoclonal Gammopathy\u2013Associated C3 Glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.4.939","article-title":"Sepp\u00e4l\u00e4,I.J. Activation of the Alternative Pathway of Complement by Monoclonal Lambda Light Chains in Membranoproliferative Glomerulonephritis","volume":"175","author":"Meri","year":"1992","journal-title":"J Exp Med"},{"key":"B39","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.4049\/jimmunol.163.8.4590","article-title":"Nephritogenic \u03bb Light Chain Dimer: A Unique Human Miniautoantibody Against Complement Factor H","volume":"163","author":"Jokiranta","year":"1999","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.2215\/CJN.06180710","article-title":"Glomerulonephritis With Isolated C3 Deposits and Monoclonal Gammopathy: A Fortuitous Association","volume":"6","author":"Bridoux","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2013.02.370","article-title":"C3 Glomerulonephritis Associated With Monoclonal Gammopathy: A Case Series","volume":"62","author":"Zand","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.01.037","article-title":"C3 Glomerulopathy Associated With Monoclonal Ig Is a Distinct Subtype","volume":"94","author":"Ravindran","year":"2018","journal-title":"Kidney Int"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/MBC.0b013e32830610ee","article-title":"Thrombotic Thrombocytopenic Purpura Associated With Multiple Myeloma","volume":"19","author":"Alpay","year":"2008","journal-title":"Blood Coagulation Fibrinol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.5414\/cn107579","article-title":"Thrombotic Thrombocytopenic Purpura Due to Anti-ADAMTS13 Antibodies in Multiple Myeloma","volume":"81","author":"Yao","year":"2014","journal-title":"Clin Nephrol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2421-0","article-title":"Thrombotic Thrombocytopenic Purpura in a Patient With Lenalidomide-Responsive Multiple Myeloma","volume":"94","author":"Cheah","year":"2015","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"106195","DOI":"10.1016\/j.leukres.2019.106195","article-title":"A Review of Thrombotic Microangiopathies in Multiple Myeloma","volume":"85","author":"Portuguese","year":"2019","journal-title":"Leuk Res"},{"key":"B47","doi-asserted-by":"crossref","first-page":"101081","DOI":"10.1016\/j.tranon.2021.101081","article-title":"Thrombotic Microangiopathy in Oncology - A Review","volume":"14","author":"Val\u00e9rio","year":"2021","journal-title":"Transl Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24662","article-title":"Ixazomib-Induced Thrombotic Microangiopathy","volume":"92","author":"Yui","year":"2017","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25208","article-title":"Drug-Induced Thrombotic Microangiopathy: An Updated Systematic Review, 2014-2018","volume":"93","author":"Saleem","year":"2018","journal-title":"Am J Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00212","article-title":"An Update in Drug-Induced Thrombotic Microangiopathy","volume":"7","author":"Chatzikonstantinou","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2005.12.040","article-title":"Thrombotic Nephropathy and Pulmonary Hypertension Following Autologous Bone Marrow Transplantation in a Patient With Acute Lymphoblastic Leukemia: Case Report","volume":"38","author":"Perkowska-Ptasinska","year":"2006","journal-title":"Transplant Proc"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0159-8","article-title":"High-Dose Carboplatin\/Etoposide\/Melphalan Increases Risk of Thrombotic Microangiopathy and Organ Injury After Autologous Stem Cell Transplantation in Patients With Neuroblastoma","volume":"53","author":"Jodele","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.5414\/CN108363","article-title":"Refractory Atypical Hemolytic Uremic Syndrome With Monoclonal Gammopathy Responsive to Bortezomib-Based Therapy","volume":"83","author":"Cheungpasitporn","year":"2015","journal-title":"Clin Nephrol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-010-1569-0","article-title":"Renal Thrombotic Microangiopathies\/Thrombotic Thrombocytopenic Purpura in a Patient With Primary Sj\u00f6gren's Syndrome Complicated With IgM Monoclonal Gammopathy of Undetermined Significance","volume":"33","author":"Koga","year":"2013","journal-title":"Rheumatol Int"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.10.020","article-title":"Proliferative C4 Dense Deposit Disease, Acute Thrombotic Microangiopathy, a Monoclonal Gammopathy, and Acute Kidney Failure","volume":"67","author":"Ali","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B56","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.kint.2017.04.039","article-title":"Complement-Dependent, Monoclonal Gammapathy-Associated Thrombotic Microangiopathy","volume":"92","author":"Schurder","year":"2017","journal-title":"Kidney Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12934","article-title":"Monoclonal Gammopathy of Renal Significance Triggering Atypical Haemolytic Uraemic Syndrome","volume":"22","author":"Mahmood","year":"2017","journal-title":"Nephrology"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.09.045","article-title":"Thrombotic Microangiopathy Associated With Monoclonal Gammopathy","volume":"91","author":"Ravindran","year":"2017","journal-title":"Kidney Int"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25569","article-title":"Monoclonal Gammopathy-Associated Thrombotic Microangiopathy","volume":"94","author":"Yui","year":"2019","journal-title":"Am J Hematol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","article-title":"Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse After Eculizumab Discontinuation","volume":"12","author":"Fakhouri","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2012.195","article-title":"STEC-HUS, Atypical HUS and TTP Are All Diseases of Complement Activation","volume":"8","author":"Noris","year":"2012","journal-title":"Nat Rev Nephrol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1100859","article-title":"Eculizumab in Severe Shiga-Toxin-Associated HUS","volume":"364","author":"Lapeyraque","year":"2011","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2012.09084.x","article-title":"Eculizumab in the Treatment of Refractory Idiopathic Thrombotic Thrombocytopenic Purpura","volume":"157","author":"Chapin","year":"2012","journal-title":"Br J Haematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"364","DOI":"10.2215\/CJN.05830518","article-title":"Complement Gene Variants and Shiga Toxin\u2013Producing Escherichia Coli\u2013Associated Hemolytic Uremic Syndrome","volume":"14","author":"Fr\u00e9meaux-Bacchi","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1681\/ASN.2018020184","article-title":"C5b9 Formation on Endothelial Cells Reflects Complement Defects Among Patients With Renal Thrombotic Microangiopathy and Severe Hypertension","volume":"29","author":"Timmermans","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","article-title":"Severe and Malignant Hypertension Are Common in Primary Atypical Hemolytic Uremic Syndrome","volume":"96","author":"Cavero","year":"2019","journal-title":"Kidney Int"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.119.13714","article-title":"Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy","volume":"75","author":"Timmermans","year":"2020","journal-title":"Hypertension"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1053\/j.ackd.2020.01.002","article-title":"Complement-Mediated Disorders in Pregnancy","volume":"27","author":"Amari Chinchilla","year":"2020","journal-title":"Adv Chronic Kidney Dis Complement Kidney Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfw453","article-title":"Eculizumab in Secondary Atypical Haemolytic Uraemic Syndrome","volume":"32","author":"Cavero","year":"2017","journal-title":"Nephrol Dial Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.780107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,14]],"date-time":"2023-01-14T15:48:10Z","timestamp":1673711290000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.780107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":69,"alternative-id":["10.3389\/fimmu.2021.780107"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.780107","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"article-number":"780107"}}